White & Case (New York)

Jack E. Pace

White & Case (New York)
Lawyer (Partner)

Mr. Pace is a member of White & Case’s Global Competition and Commercial Litigation Practice Groups. He concentrates on complex commercial litigation and counseling in the areas of antitrust and trade regulation. Mr. Pace has extensive experience defending companies in complex, multi-jurisdictional class actions, including those involving claims under the antitrust laws, consumer protection statutes and Title VII. Mr. Pace regularly represents clients in the pharmaceutical, financial services, agricultural and insurance industries. Mr. Pace is an Associate Editor of Antitrust Magazine and regularly publishes articles on antitrust law, class certification and other complex commercial litigation topics. Mr. Pace is a member of White & Case’s Knowledge and Technology Committee and has many years of experience advising clients on e-discovery issues such as document retention policies, document collection and discovery management. Mr. Pace is a member of the Board of Directors of Reach Out and Read of Greater New York, a not-for-profit organization focusing on pediatric literacy. He also serves as liaison in connection with the Firm’s work with inMotion, a not-for-profit organization that provides free legal and social services to low income women in New York City, and supervises the Firm’s pro bono special education cases.

Distinctions

Linked authors

White & Case (Brussels)
White & Case (Washington)
White & Case (New York)
White & Case (Washington)
White & Case (New York)

Videos

Jack Pace (White & Case)
Jack E. Pace 31 May 2019 New York

Articles

1522 Bulletin

Mark J. Gidley, George Paul, Jack E. Pace, Kathryn Jordan Mims, Kristen O’Shaughnessy, Kevin Adam, Jaclyn Phillips, Abdul Hafiz, Erin McNamee The US President Joe Biden signs an executive order instructing more than a dozen federal agencies to promptly tackle some of the most pressing competition problems across the national economy

114

A new Executive Order signed by President Biden includes 72 initiatives instructing more than a dozen federal agencies, including the US Department of Justice and the Federal Trade Commission, to, according to the White House’s Fact Sheet, "promptly tackle some of the most pressing competition (...)

Jack E. Pace, Kristen O’Shaughnessy, Robert Milne, Peter J. Carney, Michael Gallagher, Mark J. Gidley, Kevin Adam The US Congress proposes a package of bills on drug pricing, including changes to the treatment of reverse payments, product hopping, sham petitions, and patent dancing

144

What’s next for drug pricing in the US? Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers, while the growing web of state laws is expected to increase compliance challenges for the pharmaceutical industry. What’s changing? A new (...)

Jack E. Pace, Scott Hershman, Andrew Hammond, Ian Cuillerier, Tripp Odom, Edward So, Pratin Vallabhaneni The US DoJ releases a positive Business Review Letter blessing the amendments of the International Swaps and Derivatives Association to address interest rate benchmarks (International Swaps and Derivatives Association)

107

For the thousands of financial institutions anxiously watching the discontinuation and transition from certain interbank offered rates (“IBORs”), 2020 just got a little less chaotic. On Thursday, October 1, 2020, the United States Department of Justice Antitrust Division issued its highly (...)

Mark J. Gidley, Noah A. Brumfield, Jack E. Pace, Kristen O’Shaughnessy, Dan Grossbaum, Bryan D. Gant The US State of California becomes the first State to enact legislation rendering certain pharmaceutical patent litigation settlement agreements presumptively anticompetitive

106

This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On October 7, 2019, California became the first state to enact legislation— Assembly Bill 824 (“AB 824”)—rendering certain pharmaceutical patent litigation settlement (...)

Agatha Koprowski, Jack E. Pace, Max Shterngel, Owen Pell, Robert Milne, Scott Hershman The New York Court of Appeals holds that state law cannot reach a purely foreign antitrust conspiracy (Global Reinsurance / Equitas)

284

In a decision that may reverberate beyond the antitrust context, New York’s highest court - the Court of Appeals - held that the state’s antitrust statute lacks the extraterritorial scope to reach a purely foreign alleged antitrust conspiracy. The decision could have broad implications for (...)

George Paul, Jack E. Pace, Joseph Angland, Mark J. Gidley, Martin M. Toto, Robert Milne The Department of Justice withdraws the report untitled Competition and Monopoly (Single-Firm Conduct under Section 2 of the Sherman Act that had been issued by the Division in September 2008)

114

On May 11, 2009, the Antitrust Division of the Department of Justice (“DOJ”), in a speech by new Assistant Attorney General Christine A. Varney and a press release issued later in the day, formally withdrew the report entitled Competition and Monopoly: Single-Firm Conduct under Section 2 of the (...)

Send a message